HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor

Abstract

ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.